Relative Strength Index (RSI)
|Bid||0.00 x 900|
|Ask||12.99 x 1200|
|Day's Range||12.42 - 12.94|
|52 Week Range||1.50 - 13.91|
|Beta (5Y Monthly)||3.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) of its common stock, par value $0.001 per share. All of the common stock was sold at a public offering price of $9.75 per share for total gross proceeds to Celldex of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. With the closing of this offering, Celldex believes that the cash, cash equivalents and marketable securities at June 18, 2020 are sufficient to meet estimated working capital requirements and fund currently planned operations through 2023.
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a price to the public of $9.75 per share. In connection with the offering, Celldex has also granted the underwriter a 30-day option to purchase up to an additional 2,006,688 shares of common stock offered in the public offering, at the same public offering price per share less underwriting discounts and commissions.
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30‐day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company.
Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price. SVP of Corp Affairs & Admin Cavanaugh Sarah filed a Form 4 with the SEC on Thursday, June 11. The insider bought 1,050 shares at an average price of $4.83. After the transaction, the executive's stake in Celldex Therapeutics Inc. moved to 1,367 shares.The Importance of Insider Transactions While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision. Insiders buying stock after a notable sell off can indicate an insider's long-term belief in the success of the company; insiders buying stock at new highs can be an indication the exec doesn't feel the stock is overvalued. Conversely, insiders who are selling stock at new lows can potentially indicate some kind of capitulation moment. Insiders selling at new highs can indicate that exec wants to "take some profit" and "lock in a gain."Transaction Codes To Focus On Investors prefer focusing on transactions which take place in the open market, indicated in the Form 4 with codes P for purchase and S for sale. if the transaction was an open-market transaction, that means that the insider made a concious decision for the company's stock moving forward. Transaction codes besides P or S aren't relatively important as they are seldom tied to a decision by the executive. For example, transaction code A is indicative of an insider being forced to sell shares to attaincompensation. Moreover, transaction code C indicates the conversion of an option.See more from Benzinga * Insider Buys Celldex Therapeutics' Shares * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, June 10 showed that Executive VP & CSO Keler Tibor bought 5,000 shares at an average price of $2.99. The transaction moved the executive's stake in Celldex Therapeutics Inc. to 7,357 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision. Insiders buying stock after a notable sell off can indicate an insider's long-term belief in the success of the company; insiders buying stock at new highs can be an indication the exec doesn't feel the stock is overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain. "Important Transaction Codes Investors prefer focusing on transactions which take place in the open market, indicated in the Form 4 with codes P for purchase and S for sale. if the transaction was an open-market transaction, that means that the insider made a concious decision for the company's stock moving forward. Transaction codes other than P or S are often viewed with less conviction as they are often not tied to a decision by the exec. As an example, transaction code C indicates the conversion of an option. Transaction code A indicates the insider may have been forced to sell shares in order to receive compensation the exec was promised upon being hired by a company.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) (announced a positive readout for the Phase 1 study of KIT inhibitor CDX-0159) * Enochian Biosciences Inc (NASDAQ: ENOB) (moved on positive outcome from a preliminary FDA meeting regarding its HIV treatment candidate that could lead to pre-IND filing) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Phathom Pharmaceuticals Inc (NASDAQ: PHAT) * Replimune Group Inc (NASDAQ: REPL) * Sarepta Therapeutics Inc (NASDAQ: SRPT) (announced positive results from a study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zynex Inc. (NASDAQ: ZYXI)None of the NYSE- or Nasdaq-listed biopharma/medical diagnostics stocks hit 52-week lows Monday.Stocks In Focus Shockwave's IVL Procedure Gets CMS Code For Medicare Reimbursement Shockwave Medical Inc (NASDAQ: SWAV) said the Centers for Medicare & Medicaid Services issued new codes for intravascular lithotripsy, or IVL, procedures performed in peripheral arteries in both the hospital outpatient and inpatient settings.These outpatient and inpatient codes will go into effect July 1 and Oct. 1, respectively. Shockwave develops and markets IVL to treat complex calcified cardiovascular disease.Under these new codes, Medicare payment rates for IVL procedures performed in the hospital outpatient and inpatient settings are consistent with payment levels for other similar peripheral artery interventional procedures, Shockwave said.The stock added 9.13% to $49.11 in after-hours trading.Sanofi Announces Breast Cancer Combo Therapy Collaboration With Hong Kong's Alphamab Sanofi SA (NASDAQ: SNY) announced an agreement with Hong Kong-based biopharma Alphamab Oncology to establish a strategic collaboration to investigate the latter's KN026 in combination with Taxotere in HER2+ breast cancer. Sanofi is also granted an exclusivity period to negotiate the in-licensing of KN026, subject to the achievement of certain clinical milestones.KN026 is an anti-HER2 bispecific antibody that has shown promising preliminary efficacy and excellent safety profile in late-stage breast cancer patients who have failed multiple treatments in China.Soleno Says Late-Stage Study Of Genetic Disorder Drug Fails To Meet Primary Goal Soleno Therapeutics Inc (NASDAQ: SLNO) said its Phase 3 trial evaluating once-daily Diazoxide Choline Controlled Release, or DCCR, tablets for patients with Prader-Willi Syndrome did not meet its primary endpoint of change from baseline in hyperphagia.The company, however, said top-line results showed significant positive changes in two of the three key secondary points. It also said interim analysis of the ongoing extension study showed further reductions in hyperphagia of 48% after six months of DCCR treatment.The stock was down 48.15% at $1.68 premarket Tuesday. See also: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage NanoViricides' Coronavirus Candidates Found Superior To Remdesivir In Animal Models NanoViricides Inc (NYSE: NNVC) said it has signed a memorandum of understanding with respect to antiviral treatments for coronavirus-derived human infections with TheraCour Pharma. The MoU specifically provides a limited, exclusive license to all R&D toward human clinical trials. NanoViricides said it intends to retain an independent consultant for the evaluation of the assets in order to develop the full license agreement. The company said the broad-spectrum anti-coronavirus drug candidates that it is developing showed strong effectiveness in an animal model of human coronavirus disease, potentially superior to remdesivir in this particular model.The company cautioned that no conclusions to that effect can be drawn with the limited dataset. NanoViricides said prior to filing for human clinical trials, it plans on conducting studies to further determine the effectiveness against SARS-CoV-2, perform drug development studies for safety/toxicology and request a pre-IND Meeting with the FDA for regulatory guidance.The stock was up 7.18% at $7.02 premarket. Agios Blood Disorder Drug Receives Orphan Desgination Agios Pharmaceuticals Inc (NASDAQ: AGIO) said the FDA granted an orphan drug designation to its first-in-class pyruvate kinase-R activator mitapivat for the treatment of patients with thalassemia.Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.The stock advanced 1.68% to $53.11 in after-hours trading.Global Blood To Seek Label Expansion For Sickle Cell Disease Drug Global Blood Therapeutics Inc (NASDAQ: GBT) said it plans to seek label expansion for the potential use of Oxbryta for the treatment of sickle cell disease in children ages 4-11 following a Type B meeting with the FDA.View more earnings on IBBIt is currently approved in the U.S. to treat SCD in adults and adolescents 12 and older.The stock gained 4.8% to $69 in after-hours trading.Ardelyz Appoints Justin Renz As CFO Ardelyx Inc (NASDAQ: ARDX) announced the appointment of biopharma industry veteran Justin Renz to the position of CFO.Erytech Pharma Reports Positive Preliminary Results For Leukemia Drug In an update on the ongoing Phase 2 trial of eryaspase in second-line acute lymphoblastic leukemia patients, Erytech Pharma SA (NASDAQ: ERYP) said the trial, which is being conducted at 22 clinical sites in the Nordic and Baltic countries of Europe, has reached its target enrollment of 50 patients. The company also said preliminary findings from the study suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients.Additionally, the addition of eryaspase to the combination chemotherapy was associated with an acceptable tolerability profile, enabling the majority of these patients to receive their fully intended courses of asparginase.Enzo Biochem Posts Q3 Loss Enzo Biochem, Inc.'s (NYSE: ENZ) third-quarter revenues fell 14% year-over-year to $16.9 million, dragged by a 28% reduction in accession volume due to factors related to the COVID-19 pandemic. The company reversed from a profit of 47 cents per share to a loss of 21 cents per share.The stock moved down 6.57% to $2.56 in after-hours trading.Offerings Cerecor Inc (NASDAQ: CERC) said it intends to offer for sale shares of its common stock in an underwritten public offering. All the shares are being offered by Cerecor.The stock retreated 9.94% to $2.90 in after-hours trading.Replimune priced its upsized public offering of 2.826 million shares at $23 per share. The company also said it priced the public offering of pre-funded warrants to purchase 1.523 million of its common stock at $22.999 per pre-funded warrant. The company expects to raise $100 million in aggregate gross proceeds. All the securities earmarked for the offering are sold by the company. The company expects the offering to close June 11.The stock was plunging 17.39% to $2.66 premarket. Retrophin Inc (NASDAQ: RTRX) priced its underwritten public offering of 6.5 million shares of its common stock at $15.50 per share for gross proceeds of about $100.8 million. All of the shares are being sold by the company. The offering is expected to close June 11.In after-hours trading, the stock fell 3.44% to $15.98.Fate Therapeutics Inc (NASDAQ: FATE) priced its underwritten public offering of 6.182 million shares of its common stock at $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. All shares of common stock to be sold in the offering are being offered by the company. The offering is expected to close on or about June 11.The stock rose 2.44% to $29 in after-hours trading.On The Radar Clinical Readouts, Presentations Novavax, Inc. (NASDAQ: NVAX) said its President of Research and Development Gregory Glenn will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital, discussing COVID-19 vaccines. The panel discussion is scheduled for 11:30 am.Related Link: Novavax Analyst Says DoD Funding Reflects Conviction In Platform, Ability To Deliver On Vaccine See more from Benzinga * 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Celldex Therapeutics, Inc. (CLDX) today announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects. Data (presentation #1829) were featured in a late breaking presentation today at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020. CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell suppression.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
HAMPTON, N.J., May 06, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite.
Celldex Therapeutics, Inc. (CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020, which this year will be held digitally June 6-8, 2020. The study will be presented by Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy at the Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin. Dr. Maurer is also head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus and Angioedema and the Dermatological Allergology Lab.
HAMPTON, N.J., March 26, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.
Celldex Therapeutics, Inc. (CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller University under which Celldex performed manufacturing and development services for Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including two clinical-stage candidates 3BNC117 and 10-1074. This portfolio was licensed by Gilead Sciences in January of 2020 from Rockefeller University and pursuant to Celldex’s agreement with Rockefeller, Celldex will receive an upfront payment of $1.7 million as a result of this transaction and is eligible to receive additional milestone payments as these products progress through clinical development plus royalties on potential future sales.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Celldex Therapeutics, Inc. (CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells.
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HAMPTON, N.J., Nov. 12, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019..
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s preclinical pipeline this weekend. A review of the CDX-0159 early development program was presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting on November 9, 2019 in the Distinguished Industry Oral Abstract Session. Preclinical data supporting the continued development of the Company’s CDX-527 bispecific candidate were also presented at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting (SITC 2019), including both a poster presentation on November 9, 2019 and a talk during the preconference program session “Novel Multi-Targeted Therapeutic Platforms” on Wednesday, November 6, 2019.
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s ongoing CD40 agonist program today at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex Therapeutics, Inc. (CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. CDX-1140: The abstract (Abstract ID: P827) entitled, “Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers” will be presented in a poster presentation by Rachel Sanborn, MD, Co-director of the Thoracic Oncology Program and Leader of the Phase 1 Trials Program at Providence Cancer Institute and a lead investigator in this study, on Friday, November 8, 2019 from 8:00 am to 8:00 pm ET. Michael Yellin, MD, Vice President of Clinical Science at Celldex will also present a talk entitled CD40: A Target for Systemic Immune Modulation at the Workshop on Intratumoral Immunomodulation on Thursday, November 7, 2019 at 3:00 pm ET.